Drug Lawsuits

TDF HIV Drugs Lawsuit

Open

TDF drugs are allegedly linked to kidney and bone injuries. Lawsuits will maintain that Gilead withheld a less toxic HIV drug in order to maximize profits.

Elmiron Lawsuit

Johnson & Johnson company Janssen Pharmaceuticals is facing lawsuits alleging a link between its drug Elmiron and a dangerous eye condition known as Retinal Maculopathy. 

Zantac Lawsuit

Open

If you have been diagnosed with cancer after taking Zantac, you may be eligible to file a lawsuit.

Belviq Lawsuit

According to the U.S. Food and Drug Administration (FDA), the weight-loss medication Belviq (lorcaserin) may increase the risk of cancer. A five-year study found a higher incidence of lung, pancreatic, colorectal, and other cancers in patients who took Belviq.

Valsartan Lawsuit

Open

If you have been diagnosed with cancer or suffered liver damage after taking Valsartan, you may be eligible to file a lawsuit.

Zostavax Lawsuit

Open

Merck faces lawsuits for its shingles vaccine, Zostavax. Plaintiffs allege that Zostavax caused serious injuries like shingles, blindness, and even death.

Abilify Lawsuit

Closed

The companies that manufacture and market Abilify failed to warn U.S. patients that the drug could induce compulsive behaviors like gambling.

Benicar Lawsuit

Closed

Many patients who took Benicar and related drugs suffered gastrointestinal injuries. Lawsuits against drugmaker Daiichi Sankyo resulted in a $300M settlement.

Pradaxa Lawsuit

Open

The blood thinner Pradaxa did not have an antidote for its bleeding events until 2015. They now face thousands of lawsuits.

Eliquis Lawsuit

Closed

The blood thinner Eliquis may cause life-threatening internal bleeding. Eliquis users who suffered serious bleeding events have filed lawsuits.

Victoza Lawsuit

Open

More than 700 lawsuits allege that Victoza, Byetta, and Januvia increase patients' risk of pancreatic cancer. But manufacturers, plaintiffs allege, failed to warn doctors and patients.

Tasigna Lawsuit

Open

Some lawsuits allege that Novartis failed to warn of Tasigna's risk of atherosclerosis, a disease that causes plaque to build up in the arteries.